In terms of the size, it would depend on any limitation related to our ability to finance it and how much additional profit we would generate, every case is different. Chief Executive Pascal Soriot More Quotes by Chief Executive Pascal Soriot More Quotes From Chief Executive Pascal Soriot It's early days but if this works we believe we could end up treating up to 40 percent of patients with ovarian or breast cancer and, importantly, we also have very strong pre clinical results in lung cancer, we are not only first but we are going to be first and alone for a time in DDR because there is nobody else that has this portfolio ... we will have something quite unique. Chief Executive Pascal Soriot health-news We'll have our overall survival data by Q2 or Q3 next year. Chief Executive Pascal Soriot health-news If our study in lung cancer is positive, the view people have of the company will change completely. Chief Executive Pascal Soriot health-news When you have all these great opportunities you have to then support them, this is where the investment is going - it is more clinical trials, essentially, and launch preparation. Chief Executive Pascal Soriot health-news Prices have come down and, as a result, some companies are a bit more attractive than they used to be, but prices still remain quite high, it's not that easy to find acquisitions that can be accretive immediately. Chief Executive Pascal Soriot healthcare We are not going to do any additional acquisitions that would increase the size of our pipeline. We would consider acquisitions that would be accretive, meaning they would generate additional earnings immediately. Chief Executive Pascal Soriot healthcare We're confident that our strong execution on strategy, combined with the benefits of focused investments and new launches, keeps us on track to return to sustainable growth in line with our targets. Chief Executive Pascal Soriot business
